The findings of this study revealed the similarity in the reduction of eGFR between T2DM patients treated with SGLT-2 inhibitors and DPP-4 inhibitors for 18 months, as well as the reduction in FBS and HbA1c levels. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.